Lyberg K1,2, Ali HA3,2, Grootens J1,2, Kjellander M3, Tirfing M1, Arock M4, Hägglund H5, Nilsson G1,2, Ungerstedt J3,2.
Oncotarget. 2016 Dec 25. doi: 10.18632/oncotarget.14181. [Epub ahead of print]Systemic mastocytosis (SM) is a clonal bone marrow disorder, where therapeutical options are limited. Over 90% of the patients carry the D816V point mutation in the KIT receptor that renders this receptor constitutively active. We assessed the sensitivity of primary mast cells (MC) and mast cell lines HMC1.2 (D816V mutated), ROSA (KIT WT) and ROSA (KIT D816V) cells to histone deacetylase inhibitor (HDACi) treatment. Read More